Leucid Bio Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
19
- Latest Deal Type
-
Series A1
- Latest Deal Amount
-
$9.3M
- Investors
-
7
Leucid Bio General Information
Description
Operater of a cell therapy company intended to develop novel cell therapies for patients with solid tumors and no treatment options. The company specializes in the development of chimeric antigen receptor (CAR) T-cell therapies that produce a durable response than previous CAR T generations, enabling healthcare professionals to improve treatment outcomes and save the lives of patients with refractory cancers.
Contact Information
Website
www.leucid.comCorporate Office
- 3rd Floor
- Bermondsey Wing Guys Hospital
- London SE1 9RT
- England, United Kingdom
Corporate Office
- 3rd Floor
- Bermondsey Wing Guys Hospital
- London SE1 9RT
- England, United Kingdom
Leucid Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series A1) | 01-Feb-2025 | $9.3M | Completed | Clinical Trials - Phase 2 | ||
| 4. Later Stage VC (Series A) | 21-Oct-2021 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC | 19-Dec-2019 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC | 04-Jul-2017 | $2.88M | $2.88M | Completed | Clinical Trials - Phase 1 | |
| 1. University Spin-Out | 27-Nov-2014 | Completed | Clinical Trials - Phase 1 |
Leucid Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A1 Preferred | ||||||||
| Series A1 Preferred | ||||||||
| Series A Preferred | ||||||||
| Series A Preferred | ||||||||
| Series A Preferred | 1,714,228 | $0.001235 | $3.66 | $3.66 | 1x | $3.66 | 8.99% | |
| Seed Preference | 4,250,000 | $0.001235 | $1.23 | $1.23 | 1x | $1.23 | 22.29% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Leucid Bio Comparisons
Industry
Financing
Details
Leucid Bio Competitors (3)
One of Leucid Bio’s 3 competitors is Autolus, a Formerly VC-backed company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Autolus | Formerly VC-backed | London, United Kingdom | ||||
| Cellectis | Formerly VC-backed | Paris, France | ||||
| Celyad Oncology | Formerly VC-backed | Mont-Saint-Guibert, Belgium |
Leucid Bio Patents
Leucid Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025196207-A1 | Compositions and methods for use in depleting senescent cells and treating aging | Pending | 20-Mar-2024 | ||
| GB-202403716-D0 | Parallel chimeric antigen receptors (pcars) and adaptor chimeric antigen receptors comprising alternative signalling domains and methods of use thereof | Inactive | 14-Mar-2024 | ||
| GB-202403717-D0 | Therapeutic agents | Inactive | 14-Mar-2024 | ||
| GB-202403718-D0 | Therapeutic agents | Inactive | 14-Mar-2024 | ||
| GB-202403720-D0 | Therapeutic agents | Inactive | 14-Mar-2024 |
Leucid Bio Signals
Leucid Bio Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 2invest | Corporation | Minority | ||
| 4basebio | Corporation | Minority | ||
| British Business Bank | Lender/Debt Provider | Minority | ||
| Vulpes Investment Management | Family Office | Minority | ||
| Epidarex Capital | Venture Capital | Minority |
Leucid Bio FAQs
-
When was Leucid Bio founded?
Leucid Bio was founded in 2014.
-
Where is Leucid Bio headquartered?
Leucid Bio is headquartered in London, United Kingdom.
-
What is the size of Leucid Bio?
Leucid Bio has 19 total employees.
-
What industry is Leucid Bio in?
Leucid Bio’s primary industry is Drug Discovery.
-
Is Leucid Bio a private or public company?
Leucid Bio is a Private company.
-
What is the current valuation of Leucid Bio?
The current valuation of Leucid Bio is .
-
What is Leucid Bio’s current revenue?
The current revenue for Leucid Bio is .
-
How much funding has Leucid Bio raised over time?
Leucid Bio has raised $30.6M.
-
Who are Leucid Bio’s investors?
2invest, 4basebio, British Business Bank, Vulpes Investment Management, and Epidarex Capital are 5 of 7 investors who have invested in Leucid Bio.
-
Who are Leucid Bio’s competitors?
Autolus, Cellectis, and Celyad Oncology are competitors of Leucid Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process